Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Double-blind, Vehicle-controlled, Phase-2 Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients

Trial Profile

A Multi-center, Randomized, Double-blind, Vehicle-controlled, Phase-2 Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2019

At a glance

  • Drugs VBP 926 (Primary)
  • Indications Paronychia
  • Focus Therapeutic Use
  • Sponsors Veloce BioPharma
  • Most Recent Events

    • 09 Oct 2018 Status changed from active, no longer recruiting to completed.
    • 03 Oct 2018 According to a Veloce BioPharma media release, Mario Lacouture, MD, Director, Oncodermatology Program at Memorial Sloan Kettering Cancer Center is one of the lead investigators of the study.
    • 03 Oct 2018 Primary endpoint has been met. (Downgrading of the 6-point Paronychia Severity Grading scale (adapted from CTCAE v4.0) in adult cancer patients with chemotherapy-associated paronychia)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top